A collaborative effort between Duke-NUS Medical School and the National University of Singapore Yong Loo Lin School of Medicine (NUS Medicine) has led to the launch of the joint research centre named Systems Metabolomics Centre (SysMeC), aimed at metabolomics research.
Vivus has received approval in the United Arab Emirates (UAE) to market Qsymia (phentermine and topiramate extended-release capsules) CIV for treating obesity and overweight in adults and paediatric individuals aged 12 and above.
Laekna has entered into a clinical partnership with Eli Lilly to advance the development of LAE102, a new ActRIIA monoclonal antibody for treating obesity.
Machine learning-enabled drug discovery and development company insitro has executed three agreements with Lilly to advance new treatments for metabolic diseases.
Diamyd Medical has announced the receipt of fast track designation from the US Food and Drug Administration (FDA) for type 1 diabetes treatment, Diamyd.
Aardvark Therapeutics has secured $85m in an oversubscribed Series C financing round, with Decheng Capital spearheading the investment, to complete studies of ARD-101.
Rhythm Pharmaceuticals and Genpharm Services FZ have announced a partnership to commercialise IMCIVREE (setmelanotide) for patients in Gulf Cooperation Council (GCC) countries.
Rhythm Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for IMCIVREE (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for patients with Bardet-Biedl syndrome (BBS).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.